Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Cancer Research

• Publication date

  1992-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 1322791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA Topoisomerase II Is Required at the Time of Mitosis in Yeast

  2004cited by this paper
• Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II.

  1992cited by this paper
• DNA topoisomerases: why so many?

  1991cited by this paper
• Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

  1991cited by this paper
• Genetic analysis of the gyrase A-like domain of DNA topoisomerase II of Saccharomyces cerevisiae.

  1991cited by this paper
• Mechanisms of resistance to drugs that inhibit DNA topoisomerases.

  1991cited by this paper
• DNA topology and its biological effects

  1990cited by this paper
• DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli

  1990cited by this paper
• [Inhibitors of DNA topoisomerases].

  1990cited by this paper
• DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

  1989cited by this paper
• High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier

  1989cited by this paper
• Topoisomerase-targeting antitumor drugs.

  1989cited by this paper
• DNA topoisomerase poisons as antitumor drugs.

  1989cited by this paper
• Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae.

  1989cited by this paper
• A subthreshold level of DNA topoisomerases leads to the excision of yeast rDNA as extrachromosomal rings.

  1989cited by this paper
• gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli

  1989cited by this paper
• Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.

  1989cited by this paper
• Inhibitors of DNA topoisomerases.

  1988cited by this paper
• Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.

  1988cited by this paper
• Altered function of DNA topoisomerases as a basis for antineoplastic drug action.

  1988cited by this paper
• Supercoiling of intracellular DNA can occur in eukaryotic cells.

  1988cited by this paper
• Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.

  1988influential reference
• Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22.

  1988cited by this paper
• DNA topoisomerase-targeting antitumor drugs can be studied in yeast.

  1988influential reference
• A Saccharomyces cerevisiae genomic plasmid bank based on a centromere-containing shuttle vector.

  1987cited by this paper
• Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli

  1986cited by this paper
• Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli

  1986cited by this paper
• Functional dissection of a eukaryotic transcriptional activator protein, GCN4 of yeast.

  1986cited by this paper
• Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase.

  1986cited by this paper
• Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

  1985cited by this paper
• DNA topoisomerase II is required at the time of mitosis in yeast.

  1985cited by this paper
• DNA topoisomerases.

  1985cited by this paper
• DNA topoisomerases: enzymes that control DNA conformation.

  1985cited by this paper
• A positive selection for mutants lacking orotidine-5′-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance

  1984cited by this paper
• Yeast DNA topoisomerase II is encoded by a single-copy, essential gene.

  1984cited by this paper
• Transformation of intact yeast cells treated with alkali cations.

  1984cited by this paper
• Isolation and characterization of yeast DNA repair genes

  1983cited by this paper
• Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases.

  1981cited by this paper
• DNA gyrase and the supercoiling of DNA.

  1980cited by this paper
• Replacement of chromosome segments with altered DNA sequences constructed in vitro.

  1979cited by this paper
• Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.

  1977cited by this paper
• Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

  1977cited by this paper
• Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase.

  1976cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Yeast Tools for Studying Type II Topoisomerases in Budding Yeast.

  2025cites this paper
• Conformations of the three gates in Saccharomyces cerevisiae topoisomerase II and their response to DNA, nucleotide, and etoposide

  2025cites this paper
• Structural insights into the assembly of type IIA topoisomerase DNA cleavage-religation center

  2024cites this paper
• Modeling Allosteric Mechanisms of Eukaryotic Type II Topoisomerases

  2023cites this paper
• Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers

  2022cites this paper
• A simplified and easy‐to‐use HIP HOP assay provides insights into chalcone antifungal mechanisms of action

  2022cites this paper
• Control of topoisomerase II activity and chemotherapeutic inhibition by TCA cycle metabolites

  2021cites this paper
• Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast

  2020cites this paper
• A conserved SUMO-Ubiquitin pathway directed by RNF4/SLX5-SLX8 and PIAS4/SIZ1 drives proteasomal degradation of topoisomerase DNA-protein crosslinks

  2019cites this paper
• A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents

  2019cites this paper
• 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.

  2018cites this paper
• Imidazoles as potential anticancer agents.

  2017cites this paper
• MYCN, proliferative heterogeneity and treatment responsein neuroblastoma

  2017cites this paper
• Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in Saccharomyces cerevisiae

  2017influential citation
• Oxidative stress and aging: Learning from yeast lessons.

  2017cites this paper
• Chemical probes: The many genes of drug mechanism.

  2016cites this paper
• Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5′ Adducts

  2016cites this paper
• Characterization of malignant pleural mesothelioma : possibilities for an individualized therapeutic arsenal

  2014cites this paper
• Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.

  2014cites this paper
• Defective histone supply causes condensin-dependent chromatin alterations, SAC activation and chromosome decatenation impairment

  2014cites this paper
• THE PRECLINICAL AND CLINICAL PHARMACOLOGY OF BENZALDEHYDE DIMETHANE SULFONATE (BEN) FOR THE TREATMENT OF RENAL CELL CARCINOMA

  2014cites this paper
• Defective histone supply causes condensin-dependent chromatin alterations, SAC activation and chromosome decatenation impairment

  2014cites this paper
• Opposing effects of target overexpression reveal drug mechanisms

  2014cites this paper
• TDP2 protects transcription from abortive topoisomerase activity and is required for normal neural function

  2014cites this paper
• Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.

  2013cites this paper
• The Anticancer Ruthenium Complex KP1019 Induces DNA Damage, Leading to Cell Cycle Delay and Cell Death in Saccharomyces cerevisiae

  2013influential citation
• Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.

  2013cites this paper
• 3-Formylchromone based topoisomerase IIα inhibitors: discovery of potent leads

  2013cites this paper
• Topoisomerase II Inhibitors: Chemical Biology

  2012cites this paper
• Chemical reactivity and microbicidal action of bethoxazin.

  2012cites this paper
• Repair of Topoisomerase II-Mediated DNA Damage: Fixing DNA Damage Arising from a Protein Covalently Trapped on DNA

  2012cites this paper
• Ubiquitin and Ubiquitin-Like Proteins in Repair of Topoisomerase-Mediated DNA Damage

  2012cites this paper
• A topoisomerase II poison screen of ethnomedicinal Thai plants using a yeast cell-based assay.

  2012cites this paper
• Ruthenium Complex KP 1019 Induces DNA Damage , Leading to Cell Cycle Delay and Cell Death in Saccharomyces cerevisiae

  2012cites this paper
• Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells

  2011cites this paper
• N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.

  2011cites this paper
• Microarray-based target identification using drug hypersensitive fission yeast expressing ORFeome.

  2011cites this paper
• Topoisomerase IIα‐dependent induction of a persistent DNA damage response in response to transient etoposide exposure

  2010cites this paper
• A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage

  2009cites this paper
• Targeting DNA topoisomerase II in cancer chemotherapy

  2009cites this paper
• Design of phenotypic screens for bioactive chemicals and identification of their targets by genetic and proteomic approaches.

  2008cites this paper
• Enhancing Drug Accumulation in Saccharomyces cerevisiae by Repression of Pleiotropic Drug Resistance Genes with Chimeric Transcription Repressors

  2008cites this paper
• Upregulation of topoisomerase IIα expression in advanced gallbladder carcinoma: a potential chemotherapeutic target

  2008cites this paper
• Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.

  2008cites this paper
• Isolation and Characterization of mAMSA-hypersensitive Mutants

  2008cites this paper
• Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.

  2008cites this paper
• Inhibition of Synthesis by Suppresses Topoisomerase II a Subunit De Novo Specific Antisense Oligonucleotides

  2007cites this paper
• Using Yeast Tools to Dissect the Action of Anticancer Drugs: Mechanisms of Enzyme Inhibition and Cell Killing by Agents Targeting DNA Topoisomerases

  2007cites this paper
• Topoisomerase IIα expression correlates with diminished disease-free survival in invasive breast cancer

  2006cites this paper
• Roles of nonhomologous end-joining pathways in surviving topoisomerase II–mediated DNA damage

  2006cites this paper
• Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.

  2006cites this paper
• Aclacinomycin A Stabilizes Topoisomerase I Covalent Complexes1

  2006cites this paper
• in Yeast α Human DNA Topoisomerase II Topoisomerases : Expression of a Functional Recombinant Use of Yeast in the Study of Anticancer Drugs Targeting DNA Updated

  2006cites this paper
• Topoisomerase deficiencies subtly enhance global genomic repair of ultraviolet-induced DNA damage in Saccharomyces cerevisiae.

  2006cites this paper
• Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer.

  2006cites this paper
• Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II

  2005cites this paper
• Large-scale analysis of genes that alter sensitivity to the anti-cancer drug tirapazamine in Saccharomyces cerevisiae.

  2005cites this paper
• Interaction of the Plasmid-Encoded Quinolone Resistance Protein Qnr with Escherichia coli DNA Gyrase

  2005cites this paper
• Induction of petite mutants in yeast Saccharomyces cerevisiae by the anticancer drug dequalinium.

  2005cites this paper
• Endonucleolytic processing of covalent protein-linked DNA double-strand breaks

  2005cites this paper
• Activation of the Unfolded Protein Response Is Necessary and Sufficient for Reducing Topoisomerase IIα Protein Levels and Decreasing Sensitivity to Topoisomerase-Targeted Drugs

  2005cites this paper
• Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma.

  2005cites this paper
• Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.

  2005cites this paper
• Large-Scale Analysis of Genes that Alter Sensitivity to the Anticancer Drug Tirapazamine in Saccharomyces cerevisiaes⃞

  2005cites this paper
• In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin

  2004cites this paper
• A Mutation in Human Topoisomerase II α Whose Expression Is Lethal in DNA Repair-deficient Yeast Cells*

  2004cites this paper
• Biological activities of pyridoacridines.

  2004cites this paper
• Using yeast to study resistance to topoisomerase II-targeting drugs

  2004cites this paper
• DNA topoisomerases in life and death: implications in kinetoplastid protozoa.

  2004cites this paper
• Understanding the action of drugs targeting TOP2: Yeast based systems for unraveling drug mechanisms

  2003cites this paper
• Degradation of topoisomerase cleavable complexes

  2003cites this paper
• DNA Topoisomerases in Cancer Therapy

  2003cites this paper
• Mechanism of action of topoisomerase II-targeted anticancer drugs

  2003cites this paper
• Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.

  2003cites this paper
• The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine.

  2003cites this paper
• The Topoisomerase IIa Expression Correlates with Survival in Patients with Advanced Hodgkin’s

  2003cites this paper
• Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.

  2003cites this paper
• Human DNA topoisomerase‐IIα expression as a prognostic factor for transitional cell carcinoma of the urinary bladder

  2003cites this paper
• Effect of the DNA topoisomerase II inhibitor VP-16 on illegitimate recombination in yeast chromosomes.

  2002cites this paper
• Antifungal Activity of Eupolauridine and Its Action on DNA Topoisomerases

  2002cites this paper
• DNA Topoisomerase II as a Target for Cancer Chemotherapy

  2002cites this paper
• Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.

  2002cites this paper
• Cell-based assays for identification of novel double-strand break-inducing agents.

  2002cites this paper
• 26 S Proteasome-mediated Degradation of Topoisomerase II Cleavable Complexes*

  2001cites this paper
• Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.

  2001cites this paper
• Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.

  2001cites this paper
• DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.

  2001cites this paper
• Overexpression of Type I Topoisomerases Sensitizes Yeast Cells to DNA Damage*

  2001cites this paper
• Anticancer drug resistance in primary human brain tumors.

  2001cites this paper
• Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.

  2000cites this paper
• Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.

  2000cites this paper
• Effects of Modifying Topoisomerase II Levels on Cellular Recovery from Radiation Damage

  2000cites this paper
• A Mutation in Yeast Topoisomerase II That Confers Hypersensitivity to Multiple Classes of Topoisomerase II Poisons*

  2000cites this paper
• Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.

  2000cites this paper
• A Novel Mechanism of Cell Killing by Anti-topoisomerase II Bisdioxopiperazines*

  2000cites this paper
• Topoisomerase II‐alpha expression in melanocytic nevi and malignant melanoma

  2000cites this paper
• Immunohistochemical staining for DNA topoisomerase II‐alpha in benign, premalignant, and malignant lesions of the prostate

  2000cites this paper
• Comparison of In Vitro Activities of Camptothecin and Nitidine Derivatives against Fungal and Cancer Cells

  1999cites this paper
• DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival.

  1999cites this paper
• Topoisomerase poisoning activity of novel disaccharide anthracyclines.

  1999cites this paper